A Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation

Phase 4

Withdrawn

• Conditions: Vertigo

• Registration Number: NCT00474409
• Lead Sponsor: Eisai Inc.

Brief Summary

The purpose of this study is to determine the efficacy and safety of Betahistine Mesilate in the treatment of patients with vertigo caused by Cerebral Infarction in posterior circulation.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-05
• Study First Submitted: 2007-05-03
• Study First Submitted QC: 2007-05-14
• Study First Posted: 2007-05-16
• Status Verified: 2017-05
• Last Update Submitted: 2017-06-01
• Last Update Posted: 2017-06-05

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Patients that have a clinical diagnosis of posterior circulation infarction and vertigo occurring within 1 month after the infarction.

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Changes in the European Evaluation of Vertigo (EEV) scale in 4 weeks.	4 weeks

Secondary Outcome Measures

Name	Time	Method
The duration of the vertigo symptom.

Trial Locations

Locations (4)

Beijing Tiantan Hospital; 🇨🇳 Beijing, Beijing, China

Beijing Hospital; 🇨🇳 Beijing, Beijing, China

Shanghai Renji Hospital; 🇨🇳 Shanghai, Shanghai, China

Shanghai Huashan Hospital; 🇨🇳 Shanghai, Shanghai, China